BPC-157 and PPIs (Omeprazole, Pantoprazole): Interaction Guide

Is there a known interaction between BPC-157 and PPIs?

An answer would have to rest on BPC-157's human pharmacology, and FDA's review describes very little of it. FDA says BPC-157's molecular targets have not been identified, that its mechanisms 'remain poorly understood', and that dose-response relationships for its reported protective effects were not established. The reported effects, such as preventing colonic fistulas and liver or gut lesions, come from rat studies rather than human trials [1].

Omeprazole, esomeprazole and pantoprazole are separate products with their own prescribing information, and their labeled uses and interactions differ [2]. The next section describes them separately.

Documented PPI interactions, product by product

PPIs can interact with other medicines by lowering stomach acid and, for omeprazole and esomeprazole, by inhibiting CYP2C19 [2].

Clopidogrel. Clopidogrel is a prodrug activated through CYP2C19. The omeprazole and Nexium labels both say to avoid concomitant use and to consider another antiplatelet drug. The omeprazole label says dosing 12 hours apart gave a similar reduction in clopidogrel's active metabolite. In healthy volunteers, omeprazole 80 mg lowered active-metabolite exposure by 46% (day 1) and 42% (day 5), and esomeprazole 40 mg lowered it by 35% to 40% [2]. Pantoprazole 80 mg lowered it about 14%, and lansoprazole 30 mg about 14%. Those labels call this not clinically important, and the Protonix label says no clopidogrel dose change is needed [2]. This is not a formal contraindication for any PPI.

Stomach acid. PPIs can reduce absorption of drugs that need stomach acid, such as iron salts, erlotinib, dasatinib, nilotinib, ketoconazole, itraconazole and mycophenolate mofetil [2]. In 12 healthy subjects, omeprazole 20 mg twice daily for 4 days lowered mycophenolic acid Cmax by 52% and AUC by 23%. The labels say the effect on organ rejection is not established and advise caution in transplant patients [2].

Other labeled interactions.

• Warfarin: PPI labels report higher INR and prothrombin time, which may lead to abnormal bleeding, and say to monitor INR and adjust the warfarin dose [2].
• Methotrexate: mainly at high dose; the labels say a temporary PPI withdrawal may be considered [2].
• Omeprazole label: limit citalopram to 20 mg per day, reduce cilostazol to 50 mg twice daily, monitor phenytoin levels, and watch for added sedation with diazepam [2].
• Digoxin and tacrolimus: the labels say to monitor concentrations [2].
• HIV drugs: rilpivirine-containing products are contraindicated with every PPI. The omeprazole label says to avoid atazanavir and nelfinavir [2].
• St. John's wort and rifampin: the omeprazole and Nexium labels say to avoid them [2].

None of these are interactions with BPC-157.

Does a PPI change how much oral BPC-157 is absorbed?

This is an open question for oral BPC-157, since FDA found no human pharmacokinetic data for it given orally, subcutaneously, nasally or on the skin [1]. After rectal enemas in two early studies, BPC-157 was mostly not detectable in blood, and FDA judged that it appears not to be absorbed systemically by that route [1]. A 2016 review of BPC 157 research describes the peptide as native and stable in human gastric juice [4].

What is known about BPC-157 in people

BPC-157 is not an FDA-approved drug, and FDA's July 2026 review found no approved product containing it in any country it searched [1]. It is a synthetic 15-amino-acid peptide described as a fragment of a protein first isolated from human gastric juice, and there is no approved dose [1].

A 2026 systematic review searching to June 1, 2026 found 3 human studies with 30 patients total in orthopaedic and regenerative use, all of poor methodological quality, with certainty of evidence rated very low. The reviewers concluded BPC-157 should not be used clinically outside ethically approved, regulated, high-quality trials [3]. FDA identified five small human studies, one a 2-person intravenous pilot, and concluded there is 'insufficient clinical safety information to characterize the safety profile' [1]. Its search of the adverse-event database through December 4, 2025 found 3 reports, all for injectable BPC-157: injection-site redness and swelling for 9 days, shortness of breath leading to an emergency room visit, and widespread skin and gum darkening that recurred on re-exposure to a BPC-157 plus TB-500 product. FDA said it cannot tell whether BPC-157 caused them [1].

On compounding, FDA's page on bulk substances that may raise significant safety risks now lists BPC-157 in a 'nominated but withdrawn' table, because the nominators withdrew; that was not a finding of safety. The page still carries FDA's concerns about immunogenicity for certain routes, peptide-related impurities and limited safety information [5][6]. On October 28, 2026 HHS filed a notice of a draft enforcement-discretion policy covering BPC-157 and five other peptides, scheduled for Federal Register publication on October 30, 2026, with public comments open for two weeks after publication [7][6]. HHS says it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians compounding with a listed peptide if the policy's conditions are met. The notice states that it does not establish any rights and is not binding on HHS or the public [7][6]. It is not an approval.

Known risks of long-term PPI use

These are labeled PPI risks. Whether BPC-157 changes any of them has not been studied.

• Low magnesium. The labels say it is reported rarely, in patients treated for at least 3 months and in most cases after a year. Serious events include tetany, arrhythmias and seizures. The labels say clinicians may check magnesium in people expected to be on prolonged treatment or also taking digoxin or diuretics [2].
• Vitamin B12. The labels say daily long-term use, for example longer than 3 years, may cause B12 malabsorption, and they call reports of deficiency rare [2].
• Other labeled risks. C. difficile-associated diarrhea (based on observational studies, especially in hospitalized patients), bone fracture (observational, higher with high-dose multiple daily doses and a year or longer), severe cutaneous reactions including SJS and TEN, cutaneous and systemic lupus, and fundic gland polyps with use beyond one year [2].
• Gastric malignancy. Symptom relief does not rule it out [2].
• Test interference. The labels say PPIs can raise chromogranin A and cause false positives in tests for neuroendocrine tumors, and that the PPI should be stopped at least 14 days before that test. They also note effects on the secretin stimulation test and reports of false-positive urine THC screens [2].